CTI BioPharma Corp. (NASDAQ:CTIC) [Trend Analysis] retains strong position in active trade, as shares scoring -0.87% to $5.73 in a active trade session, while looking at the shares volume, around 332317 shares have changed hands in this session. CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) reported positive progress on its lead programs in addition to key business priorities for 2017.
In January 2017, CTI BioPharma reported the U.S. Food and Drug Administration (FDA) removed the full clinical hold on studies being conducted under the Investigational New Drug (IND) application for pacritinib.
In December 2016, data from the randomized Phase 3 PERSIST-2 clinical trial comparing pacritinib with physician-specified best accessible therapy (BAT), including ruxolitinib, for treatment of patients with myelofibrosis whose baseline platelet counts are less than 100,000 per microliter was one of six late-breaking oral presentations at the American Society of Hematology Annual Meeting.
In January 2017, CTI BioPharma received a €7.5 million milestone payment from its partner Servier following achievement of a milestone associated with patient enrollment in the Phase 3 PIX306 clinical trial of PIXUVRI. The trial is a post-authorization trial as part of the conditional marketing authorization of PIXUVRI in the European Union (E.U.) The PIX306 is comparing PIXUVRI and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell non-Hodgkin lymphoma (NHL). The trial continues to enroll patients. The firm has institutional ownership of 25.30%, while insider ownership included 0.10%. CTIC attains analyst recommendation of 3.50 with week’s performance of 1318.06%. Investors looking further ahead will note that the Price to next year’s EPS is -38.50%.
Shares of CEVA, Inc. (NASDAQ:CEVA) [Trend Analysis] swings enthusiastically in regular trading session, it an increase of 2.10% to close at $34.00. CEVA Inc. (CEVA) declared that its fourth-quarter earnings per share exceeded the previously stated guidance range of 15-17 cents on a GAAP basis and 24-26 cents on a non-GAAP basis. Fourth-quarter revenues were approximately $21.2 million, above the high end of the company’s previously issued income guidance of $18.5 to $19.5 million. CEVA said its strong licensing demand across the CEVA technology portfolio generated more than $8 million in licensing income for the quarter.
On royalties, a one-time catch-up payment of approximately $1.1 million from a handset baseband consumer relating to prior quarters, along with good demand for CEVA-powered products, drove royalty income close to $13 million for the quarter. The company will release its full fourth quarter and year end 2016 results on February 1, 2017 before the NASDAQ market opens. Moving forward to saw long-term intention, the experts calculate Return on Investment of 2.80%. The stock is going forward its fifty-two week low with 98.71% and lagging behind from its 52-week high price with -7.63%. CEVA last month stock price volatility remained 3.10%.